U.S. Markets open in 11 mins

GH Research PLC (GHRS)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
23.74-2.73 (-10.31%)
At close: 04:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close26.47
Bid0.00 x 900
Ask30.00 x 800
Day's Range22.93 - 27.78
52 Week Range12.38 - 30.43
Avg. Volume92,174
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est32.00
  • Insider Monkey

    10 Pharma Stocks to Buy According to Mark Lampert’s Biotechnology Value Fund

    In this article, we examined Mark Lampert’s investment philosophy and decades of experience in the biotechnology space. We also reviewed 10 pharma stocks to buy according to Mark Lampert’s Biotechnology Value Fund. You can skip our detailed discussion and jump directly to 5 Pharma Stocks to Buy According to Mark Lampert’s Biotechnology Value Fund. Mark […]

  • Simply Wall St.

    We Think GH Research (NASDAQ:GHRS) Can Afford To Drive Business Growth

    Just because a business does not make any money, does not mean that the stock will go down. For example, although...

  • GlobeNewswire

    GH Research PLC Provides Business Updates and Reports Second Quarter 2021 Financial Results

    DUBLIN, Ireland, Sept. 23, 2021 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today provided business updates and reported financial results for the second quarter ended June 30, 2021. Business Updates Corporate Updates In June 2021, we completed our initial public offering, in which we issued and sold an aggregate of 11,499,999 ordinary shares, including those issu